Answers are grounded in this paper and cite their sources.
: The use of prexasertib as a monotherapy in TNBC has been limited due to modest clinical responses. We demonstrated that EGFR activation contributes to innate resistance to prexasertib in TNBC and potentially other cancers. EGFR expression status should be considered in clinical trials examining prexasertib's use as a monotherapy or combination therapy.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: